Welcome to our dedicated page for CBPO news (Ticker: CBPO), a resource for investors and traders seeking the latest updates and insights on CBPO stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect CBPO's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of CBPO's position in the market.
China Biologic Products Holdings, Inc. (NASDAQ: CBPO) has successfully completed its merger with CBPO Group Limited, becoming a wholly owned subsidiary of CBPO Holdings Limited. Shareholders will receive US$120 per share in cash, following the cancellation of their shares. Trading of CBPO shares on Nasdaq will be suspended, and a Form 25 has been filed for delisting. The company plans to suspend its reporting obligations under the Securities Exchange Act. This marks a significant shift for China Biologic as it transitions to private ownership.
China Biologic Products Holdings, Inc. (NASDAQ: CBPO) reported strong financial results for Q4 and FY 2020, showcasing resilience amid the COVID-19 pandemic. Q4 sales rose by 9.7% to $112.1 million, with gross profit increasing by 16.6% to $74.6 million and net income jumping 89.6% to $23.7 million. The fiscal year ended with total sales of $524.4 million, a 4.1% increase from 2019, and net income growing by 9.7% to $152.3 million. The company maintained its plasma collection volume and improved operational efficiency through restructuring. Looking forward, uncertainties from the pandemic persist.
China Biologic Products Holdings, Inc. (NASDAQ: CBPO) announced that its shareholders approved the merger agreement with CBPO Holdings Limited and CBPO Group Limited at an extraordinary general meeting. Approximately 84.5% of shares were voted, with 92.2% in favor of the merger plan. The merger will make China Biologic a wholly owned subsidiary of Parent, and if completed, it will no longer be listed on Nasdaq. The approval is subject to certain conditions, including the dissent rights of shareholders holding more than 8% of the company’s shares.
China Biologic Products Holdings, Inc. (NASDAQ: CBPO) announced an extraordinary general meeting (EGM) of shareholders on March 1, 2021, to vote on a merger agreement with CBPO Holdings Limited. If approved, the merger will make China Biologic a privately held company, ceasing its ordinary shares listing on Nasdaq and its registration under the Securities Exchange Act. The board unanimously supports the merger, urging shareholders of record as of February 1, 2021, to participate. Full details are available in the SEC filings and proxy materials.
China Biologic Products Holdings, Inc. (NASDAQ: CBPO) reported a 0.8% increase in total sales for Q3 2020, amounting to $138.5 million, while gross profit rose 4.4% to $92.5 million. However, net income declined by 16.0% to $39.5 million with diluted earnings per share dropping to $0.99. The company announced a merger agreement, which would take it private at $120.00 per share. Despite operational challenges, the firm is optimistic about growth from new plasma collection stations and R&D projects.
China Biologic Products Holdings, Inc. (NASDAQ: CBPO) has entered into a definitive Merger Agreement with CBPO Holdings Limited, implying an equity value of approximately US$4.76 billion. Under the agreement, each ordinary share will be exchanged for US$120.00 in cash, representing a 16.8% premium over the last trading price before the proposal. The merger is expected to close in the first half of 2021, transforming the company into a privately held entity. The Buyer Consortium, led by various investment firms, will fund the merger through a mix of equity contributions, debt financing, and company cash.
China Biologic Products Holdings, Inc. (NASDAQ: CBPO) will release its third quarter 2020 financial results on November 24, 2020, after market close. Management will conduct a conference call to discuss these results on November 25, 2020, at 7:30 a.m. ET. The call can be accessed via specific dial-in numbers provided for various regions. Additionally, a replay will be available until December 2, 2020. China Biologic is recognized as a leading plasma-based biopharmaceutical company in China, manufacturing critical therapies for serious health conditions.
China Biologic Products Holdings, Inc. (NASDAQ: CBPO) reported second quarter 2020 financial results with a 14.9% decrease in total sales, amounting to $111.1 million. Gross profit fell 16.0% to $76.4 million, while net income attributable to the company decreased 14.2% to $35.7 million compared to the previous year. Diluted EPS dropped to $0.91 from $1.06. Despite challenges from the COVID-19 pandemic, the company gained market share in direct sales channels. Advances include plans for a new plasma collection station and the approval of coagulation factor IX for manufacturing.
China Biologic Products Holdings, Inc. (NASDAQ: CBPO) plans to release its second quarter 2020 financial results on August 17, 2020, after market close. A conference call will follow on August 18, 2020, at 7:30 a.m. ET to discuss these results. Investors can access the call via specified numbers for the US, international, Hong Kong, and Mainland China. The event will be available for replay after the call until August 25, 2020. China Biologic is a leading plasma-based biopharmaceutical company in China, manufacturing over 20 diverse plasma products.
On June 29, 2020, China Biologic Products Holdings (NASDAQ: CBPO) responded to Xinjiang Deyuan's notice to terminate their cooperation agreement. The Company claims Xinjiang Deyuan has not fulfilled its obligation to supply 192 tonnes of source plasma and owes approximately RMB 248 million from a loan. China Biologic is pursuing over RMB 460 million in claims through ongoing lawsuits and has frozen shares of Xinjiang Deyuan. The Company emphasizes its commitment to legal action to protect its rights and recoup losses related to the breach of the Cooperation Agreement.
